welcome
Insider Trading & Hedge Fund Data, and Investment Newsletter From Insider Monkey

Insider Trading & Hedge Fund Data, and Investment Newsletter From Insider Monkey

Health

Health

Is Supernus Pharmaceuticals, Inc. (SUPN) the Best Pharma Stock to Buy for Long Term Growth?

Insider Trading & Hedge Fund Data, and Investment Newsletter From Insider Monkey
Summary
Nutrition label

80% Informative

Supernus Pharmaceuticals , Inc. (NASDAQ:SUPN) is a specialty company focused on developing and selling medications for central nervous system diseases, including epilepsy, migraine, and Parkinson’s disease.

About 30% of Big Pharma acquisitions involving at least $50 million upfront in 2024 involved Chinese corporations, according to DealForma statistics.

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) ranks 8th on our list of best pharma stocks to buy for long term growth.

In Q3 2024 , the company’s sales of the non-stimulant ADHD medication Qelbree increased by 68% to $62.4 million .

Small business owner?

Otherweb launches Autoblogger—a revolutionary way to bring more leads to any small business, using the power of AI.